☆ 4.7 Article

Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations

BRITISH JOURNAL OF CANCER (2019)

Journal

BRITISH JOURNAL OF CANCER

Volume 121, Issue 1, Pages 34-36

Publisher

NATURE PUBLISHING GROUP

DOI: 10.1038/s41416-019-0489-3

Keywords

-

Categories

Oncology

Funding

Citrien foundation

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Advances in molecular tumour diagnostics and the number of targeted therapies increase rapidly. Molecular tumour boards (MTBs) are designated to interpret these data and provide clinical recommendations. Not all patients with cancer have access to advice of an MTB. We aimed to determine the current status, opportunities, and challenges of the organisation of MTBs in the Netherlands. We interviewed several stakeholders about their experiences with an MTB, using template analysis. Most clinicians and patient representatives underscore the significance of an MTB, because it can stimulate rational treatment options, enrolment in clinical trials, and interdisciplinary knowledge transfer. Health insurance companies and financial managers are concerned about increasing costs. Registries to assess the clinical benefit of MTBs, guidelines on quality control, financial agreements, and logistical resources are lacking. The national organisation of MTBs and a registry of molecular and clinical data are important issues to address.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations

Bart Koopman, Harry J. M. Groen, Marjolijn J. L. Ligtenberg, Katrien Grunberg, Kim Monkhorst, Adrianus J. de Langen, Mirjam C. Boelens, Marthe S. Paats, Jan H. von der Thusen, Winand N. M. Dinjens, Nienke Solleveld, Tom van Wezel, Hans Gelderblom, Lizza E. Hendriks, Ernst-Jan M. Speel, Tom E. Theunissen, Leonie I. Kroeze, Niven Mehra, Berber Piet, Anthonie J. van der Wekken, Arja ter Elst, Wim Timens, Stefan M. Willems, Ruud W. J. Meijers, Wendy W. J. de Leng, Anne S. R. van Lindert, Teodora Radonic, Sayed M. S. Hashemi, Danielle A. M. Heideman, Ed Schuuring, Leon C. van Kempen

Summary: This study evaluates the methods and agreement in treatment recommendations among Molecular Tumor Boards (MTBs) from tertiary cancer referral centers in The Netherlands. It found that these MTBs are similar in setup and demonstrate high agreement in recommendations for rare or complex mutational cancer profiles. The proposed Dutch MTB model focuses on collaborative and nationally aligned workflow with interinstitutional collaboration and data sharing.

ONCOLOGIST (2021)

Add to Collection

Review Medicine, General & Internal

Deep Learning of Histopathological Features for the Prediction of Tumour Molecular Genetics

Pierre Murchan, Cathal O'Brien, Shane O'Connell, Ciara S. McNevin, Anne-Marie Baird, Orla Sheils, Pilib O. Broin, Stephen P. Finn

Summary: Recent advances in deep learning have been successfully applied in predicting the molecular genetics of cancers, providing valuable information for clinical decision-making and treatment, yet there are still challenges to be overcome before the clinical implementation of these technologies.

DIAGNOSTICS (2021)

Add to Collection

Review Medicine, General & Internal

Molecular Testing in Ovarian Tumours: Challenges from the Pathologist's Perspective

Kate Dinneen, Rupali Arora

Summary: The use of molecular testing in ovarian tumours has expanded rapidly, especially in relation to HRD testing in high-grade ovarian epithelial tumours. This has significant implications for pathologists in terms of increased workload and the interpretation of complex molecular pathology reports. Clear communication pathways between clinicians, pathology lab staff, and medical scientists are important to optimize the quality of reports generated. National Genomic Laboratory Hubs (GLHs) have been established in the UK to provide a uniform molecular diagnostics service, while local steps can be taken to improve tissue quality and streamline the testing process.

DIAGNOSTICS (2023)

Add to Collection

Article Oncology

Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe

Tiuri E. Kroese, Richard van Hillegersberg, Sebastian Schoppmann, Pieter R. A. J. Deseyne, Philippe Nafteux, Radka Obermannova, Marianne Nordsmark, Per Pfeiffer, Maria A. Hawkins, Elizabeth Smyth, Sheraz Markar, George B. Hanna, Edward Cheong, Asif Chaudry, Anneli Elme, Antoine Adenis, Guillaume Piessen, Cihan Gani, Christiane J. Bruns, Markus Moehler, Theodore Liakakos, John Reynolds, Alessio Morganti, Riccardo Rosati, Carlo Castoro, Domenico D'Ugo, Franco Roviello, Maria Bencivenga, Giovanni de Manzoni, Paul Jeene, Johanna W. van Sandick, Christel Muijs, Marije Slingerland, Grard Nieuwenhuijzen, Bas Wijnhoven, Laurens Beerepoot, Piotr Kolodziejczyk, Wojciech P. Polkowski, Maria Alsina, Manuel Pera, Tania F. Kanonnikoff, Magnus Nilsson, Matthias Guckenberger, Stefan Monig, Dorethea Wagner, Lucjan Wyrwicz, Maaike Berbee, Ines Gockel, Florian Lordick, Ewen A. Griffiths, Marcel Verheij, Peter S. N. van Rossum, Hanneke W. M. van Laarhoven

Summary: There is a lack of consensus on the definition and treatment of oligometastatic oesophagogastric cancer. A study was conducted to assess the definition and treatment strategies among multidisciplinary tumour boards (MDTs) in Europe. The study found a broad consensus on the definition of oligometastatic disease but high practice variability in treatment strategies.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Review Oncology

Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards

Edoardo Crimini, Matteo Repetto, Paolo Tarantino, Liliana Ascione, Gabriele Antonarelli, Elena Guerini Rocco, Massimo Barberis, Luca Mazzarella, Giuseppe Curigliano

Summary: Precision oncology aims to administer the right drug to the right patient at the right moment, overcoming the classical paradigm of one drug fits all. Molecular tumor boards (MTBs) are multidisciplinary groups that formulate the most up-to-date therapeutic or diagnostic indication for cancer patients. However, MTBs face many issues in applying these indications. This review explores these challenges and discusses possible solutions.

CANCERS (2022)

Add to Collection

Review Oncology

Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges

Blanca Trujillo, Anjui Wu, Daniel Wetterskog, Gerhardt Attard

Summary: Liquid biopsy is a powerful tool for detecting cancer aberrations in real-time, especially in prostate cancer. However, there are still challenges in screening, risk stratification, and treatment of advanced disease. Therefore, developing better biomarkers is urgently needed to guide oncologists' decisions.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Article Medicine, General & Internal

Prevalence of fluoroquinolone resistance-associated mutations in Mycoplasma genitalium among clients of two sexual health centres in the Netherlands: a cross-sectional study

Joyce F. Braam, Helene C. A. Zondag, Alje P. van Dam, Henry J. C. de Vries, Clarissa Vergunst, David Hetem, Maarten F. Schim van der Loeff, Sylvia M. Bruisten

Summary: The prevalence of fluoroquinolone resistance-associated mutations (QRAMs) in Mycoplasma genitalium (MG) among clients of two sexual health centres in the Netherlands was 9%. The most prevalent mutations were found in the parC gene (S83I and D87N) and factors associated with the presence of QRAM included men who have sex with men and Asian origin.

BMJ OPEN (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Microsatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions

Chulso Moon, Maxie Gordon, David Moon, Thomas Reynolds

Summary: Microsatellite instability is a diagnostic phenotype for various cancers, and the development of a microsatellite instability assay (MSA) associated with bladder cancer shows potential for improved detection and quality of life for patients. Over the last two decades, new molecular assays have been developed for the diagnosis of urothelial cancer, with MSA showing high sensitivity and specificity in detecting bladder cancer.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Public, Environmental & Occupational Health

NGS implementation for monitoring SARS-CoV-2 variants in Chicagoland: An institutional perspective, successes and challenges

Aileen C. Tartaninan, Nicole Mulroney, Kelly Poselenzny, Michael Akroush, Trevor Unger, Donald L. Helseth, Linda M. Sabatini, Michael Bouma, Paige M. K. Larkin

Summary: Identification of SARS-CoV-2 lineages provides valuable information for treatment efficacy, viral transmissibility, disease severity, and immune evasion. This article discusses the implementation of Next Generation Sequencing (NGS) to monitor SARS-CoV-2 lineages in the northern Chicagoland area during the pandemic, leading to crucial decisions regarding staffing, masking, and infection control measures. However, establishing the NGS procedure was challenging due to considerations such as staffing, workflow transition, data management, and IT security.

FRONTIERS IN PUBLIC HEALTH (2023)

Add to Collection

Article Oncology

Next-generation diagnostics for precision oncology: Preanalytical considerations, technical challenges, and available technologies

Wencke Walter, Nicole Pfarr, Manja Meggendorfer, Philipp Jost, Torsten Haferlach, Wilko Weichert

Summary: Molecular diagnostics has played a crucial role in precision oncology and has undergone revolutionary developments in recent years. In most cases, it is no longer possible to select treatments for cancer patients without molecular characterization. However, there has been limited scientific research on preanalytical and analytical requirements, and standardization and quality assessment have played a marginal role in the field.

SEMINARS IN CANCER BIOLOGY (2022)

Add to Collection

Article Oncology

Data-driven support to decision-making in molecular tumour boards for lymphoma: A design science approach

Nuria Rodriguez Ruiz, Sulaf Abd Own, Karin Ekstrom Smedby, Sandra Eloranta, Sabine Koch, Tove Wasterlid, Aleksandra Krstic, Magnus Boman

Summary: This study aimed to design a clinical decision support system to improve multimodal data interpretation in molecular tumor board meetings for lymphoma patients at Karolinska University Hospital in Stockholm, Sweden. The system included investigating user needs and system requirements, exploring the use of artificial intelligence, and evaluating the design with primary stakeholders. The results showed that using artificial intelligence for molecular tumor boards is a novel approach that can have a positive impact on patients.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study

Betzabel N. Cajiao Garcia, Leon C. van Kempen, Chantal C. H. J. Kuijpers, Ed Schuuring, Stefan M. Willems, Anthonie J. van der Wekken

Summary: The study aimed to determine the prevalence of KRAS mutations in stage IV nonsquamous NSCLC in the Netherlands in order to reveal the potential impact of upcoming KRAS targeted therapy. Results showed a high prevalence of KRAS p.(G12C) which provides a promising new treatment option for a subset of patients, and the national testing rate for KRAS mutations has significantly increased over the past few years.

LUNG CANCER (2022)

Add to Collection

Review Biochemical Research Methods

CRISPR-Based Diagnostics: Challenges and Potential Solutions toward Point-of-Care Applications

Ahmed Ghouneimy, Ahmed Mahas, Tin Marsic, Rashid Aman, Magdy Mahfouz

Summary: The COVID-19 pandemic has highlighted the need for decentralized Point of Care (POC) solutions in the diagnostic field. CRISPR-based diagnostics have emerged as promising tools that could revolutionize molecular diagnostics, but there are obstacles to their use in POC applications.

ACS SYNTHETIC BIOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting

Elena Sultova, C. Benedikt Westphalen, Andreas Jung, Joerg Kumbrink, Thomas Kirchner, Doris Mayr, Martina Rudelius, Steffen Ormanns, Volker Heinemann, Klaus H. Metzeler, Philipp A. Greif, Anna Hester, Sven Mahner, Nadia Harbeck, Rachel Wuerstlein

Summary: The establishment of a Molecular Tumor Board to provide personalized treatment recommendations based on molecular diagnostics has shown to be beneficial for metastatic breast cancer patients, with a high percentage of tumors having actionable genetic alterations and a significant number of patients experiencing clinical benefit from targeted therapies recommended by the board.

DIAGNOSTICS (2021)

Add to Collection

Review Microbiology

Advances and Challenges in Diagnostics of Toxoplasmosis in HIV-Infected Patients

Roland Wesolowski, Marta Pawlowska, Malgorzata Smogula, Karolina Szewczyk-Golec

Summary: Toxoplasma gondii is a globally distributed protozoan parasite that infects a third of the world's population, causing toxoplasmosis which is considered a neglected parasitic infection. Most infections in healthy individuals are asymptomatic, but the disease can be life-threatening in immunocompromised patients. HIV-infected patients have a high burden of co-infection with Toxoplasma gondii, highlighting the need for modern, sensitive, and specific methods to monitor the course of toxoplasmosis in immunodeficient patients.

PATHOGENS (2023)

Add to Collection

Article Oncology

Healthcare professionals' perspectives on implementation of universal tumor DNA testing in ovarian cancer patients: multidisciplinary focus groups

Vera M. Witjes, Joze C. C. Braspenning, Nicoline Hoogerbrugge, Yvonne H. C. M. Smolders, Dorien M. A. Hermkens, Marian J. E. Mourits, Marjolijn J. L. Ligtenberg, Margreet G. E. M. Ausems, Joanne A. de Hullu

Summary: Universal tumor DNA testing in epithelial ovarian cancer patients can serve as an efficient pre-screening tool for hereditary cancer testing and guide treatment choices. However, implementing the Tumor-First workflow requires optimal multidisciplinary collaboration and detailed standardization.

FAMILIAL CANCER (2023)

Add to Collection

Article Oncology

Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study

Tiuri E. Kroese, Yuko Takahashi, Florian Lordick, Peter S. N. van Rossum, Jelle P. Ruurda, Sjoerd M. Lagarde, Richard van Hillegersberg, Rob H. A. Verhoeven, Hanneke W. M. van Laarhoven

Summary: This population-based cohort study evaluated the treatment and survival outcomes in gastric cancer patients with liver metastases. The study found that liver oligometastatic disease and trastuzumab treatment were associated with better overall survival, while triplet chemotherapy was not significantly different from doublet chemotherapy.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study

Juergen Wolf, Edward B. Garon, Harry J. M. Groen, Daniel S. W. Tan, Isabelle Gilloteau, Sylvie Le Mouhaer, Marcio Hampe, Can Cai, Andrea Chassot-Agostinho, Maria Reynolds, Bintu Sherif, Rebecca S. Heist

Summary: Capmatinib, a MET inhibitor, showed significant antitumour activity and manageable side effects in patients with MET exon 14 (METex14)-mutated advanced non-small cell lung cancer (aNSCLC). This study reported the patient-reported outcomes (PROs) of capmatinib treatment, which demonstrated improvements in cough and quality of life (QoL) in these patients, supporting the use of capmatinib in METex14-mutated aNSCLC.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Health Care Sciences & Services

Patient-Caregiver Dyads' Prognostic Information Preferences and Perceptions in Advanced Cancer

Naomi C. A. van der Velden, Ellen M. A. Smets, Mariet Hagedoorn, Allison J. Applebaum, Bregje D. Onwuteaka-Philipsen, Hanneke W. M. van Laarhoven, Inge Henselmans

Summary: This study investigates the extent of patient-caregiver discordance in prognostic information preferences and perceptions among advanced cancer patients. The results show that there are discordances in patients' and caregivers' preferences and perceptions regarding the likelihood of cure and mortality risk. Discordant prognostic information preferences and better physical functioning of caregivers are associated with discordant perceptions of one-year mortality risk.

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2023)

Add to Collection

Article Medicine, Research & Experimental

Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors

Wesley S. van de Geer, Ron H. J. Mathijssen, Job van Riet, Neeltje Steeghs, Mariette Labots, Carla van Herpen, Lot A. Devriese, Vivianne C. G. Tjan-Heijnen, Emile E. Voest, Stefan Sleijfer, John W. M. Martens, Edwin Cuppen, Harmen J. G. van de Werken, Sander Bins

Summary: Drug resistance is a persistent problem in cancer therapy, and alterations in drug transport over the cancer cell membrane can contribute to resistance. This study analyzed the mutational landscape of transporter genes in cancer patients who had received different systemic therapies, and identified potential stressor mechanisms that may be involved in drug resistance.

BIOMEDICINE & PHARMACOTHERAPY (2023)

Add to Collection

Article Oncology

Microsatellite instability in noncolorectal and nonendometrial malignancies in patients with Lynch syndrome

Lisa Elze, Rachel S. van der Post, Janet R. Vos, Arjen R. Mensenkamp, Mirjam S. C. de Hullu, Iris D. Nagtegaal, Nicoline Hoogerbrugge, Richarda M. de Voer, Marjolijn J. L. Ligtenberg

Summary: This study aims to assess whether other tumor types in individuals with Lynch syndrome share characteristics similar to colorectal and endometrial carcinomas. Analysis of the tumor history of 1745 individuals with Lynch syndrome revealed that more than half of the malignant tumors, apart from colorectal and endometrial carcinomas, exhibit microsatellite instability (MSI-H) and mismatch repair-deficiency (dMMR). Therefore, MSI-H/dMMR testing should be conducted for all malignancies in patients with Lynch syndrome when considering therapy with immune checkpoint inhibitors.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Add to Collection

Article Oncology

Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial

H. Kievit, M. B. Muntinghe-Wagenaar, L. B. M. Hijmering-Kappelle, B. I. Hiddinga, J. F. Ubbels, R. Wijsman, G. Slingers, R. de Vries, H. J. M. Groen, H. A. M. Kerstjens, A. J. van der Wekken, T. J. N. Hiltermann

Summary: This study evaluates the safety and tolerability of Stereotactic radiotherapy combined with double Immune Checkpoint Inhibition (SICI) in advanced non-small cell lung cancer patients. The combination of SBRT and double immunotherapy is shown to be safe and feasible.

LUNG CANCER (2023)

Add to Collection

Article Multidisciplinary Sciences

Pan-cancer whole-genome comparison of primary and metastatic solid tumours

Francisco Martinez-Jimenez, Ali Movasati, Sascha Remy Brunner, Luan Nguyen, Peter Priestley, Edwin Cuppen, Arne Van Hoeck

Summary: This study characterizes the genomic differences between early-stage untreated primary tumors and late-stage treated metastatic tumors. Metastatic tumors have lower heterogeneity and a conserved karyotype, with only a modest increase in mutations. Most cancer types show either moderate or consistent genomic differences between early-stage and late-stage disease, except for breast, prostate, thyroid, kidney renal clear cell carcinomas, and pancreatic neuroendocrine tumors, which exhibit extensive genetic landscape transformation in advanced stages.

NATURE (2023)

Add to Collection

Article Genetics & Heredity

Genetic immune escape landscape in primary and metastatic cancer

Francisco Martinez-Jimenez, Peter Priestley, Charles Shale, Jonathan Baber, Erik Rozemuller, Edwin Cuppen

Summary: A pan-cancer analysis reveals the diversity of genetic immune escape mechanisms in primary and metastatic tumors, while a new tool called LILAC is presented for characterizing the HLA-I locus. The study found that one in four tumors have GIE alterations, with variability across cancer types. GIE prevalence is generally consistent between primary and metastatic tumors, and the loss of heterozygosity of HLA-I allele presents a large neoepitope repertoire.

NATURE GENETICS (2023)

Add to Collection

Article Oncology

Ri sk factors for cognitive impairment in radically treated stage III NSCLC : Secondary findings of the NVALT-11 study

Haiyan Zeng, Lizza E. L. Hendriks, Willem J. A. Witlox, Harry J. M. Groen, Anne-Marie C. Dingemans, John Praag, Jose Belderbos, Ruud Houben, Vincent van der Noort, Dirk K. M. De Ruysscher

Summary: The aim of this study was to identify risk factors for self-reported cognitive impairment in stage III non-small cell lung cancer (NSCLC) after radical treatment. Cognitive functioning was assessed at seven pre-specified time points using the EORTC-QLQ-C30. The results showed that baseline cognitive impairment was the most important risk factor for subsequent cognitive impairment in stage III NSCLC.

RADIOTHERAPY AND ONCOLOGY (2023)

Add to Collection

Review Oncology

Early-Onset Cancer in the Gastrointestinal Tract Is on the Rise-Evidence and Implications

Irit Ben-Aharon, Hanneke W. M. van Laarhoven, Elisa Fontana, Radka Obermannova, Magnus Nilsson, Florian Lordick

Summary: Data shows a significant increase in the incidence of colorectal cancer in younger populations, as well as similar trends in gastric, pancreatic, and biliary tract cancers. The majority of these cases are sporadic and not hereditary, suggesting a potential role for behavioral, lifestyle, nutritional, microbial, and environmental factors. This review explores the current understanding and challenges of early-onset gastrointestinal cancer, and emphasizes the need for further research to develop preventive strategies and tailored early detection.

CANCER DISCOVERY (2023)

Add to Collection

Article Multidisciplinary Sciences

Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer

H. C. Donker, B. van Es, M. Tamminga, G. A. Lunter, L. C. L. T. van Kempen, E. Schuuring, T. J. N. Hiltermann, H. J. M. Groen

Summary: By analyzing DNA mutations in pre-treatment tissue, researchers have identified specific mutational signatures that are associated with response to immunotherapy in advanced non-small cell lung cancer patients. This finding could potentially help select patients who are likely to benefit from immunotherapy.

SCIENTIFIC REPORTS (2023)

Add to Collection

Article Multidisciplinary Sciences

The genome-wide mutational consequences of DNA hypomethylation

Nicolle Besselink, Janneke Keijer, Carlo Vermeulen, Sander Boymans, Jeroen de Ridder, Arne van Hoeck, Edwin Cuppen, Ewart Kuijk

Summary: DNA methylation plays a crucial role in cell identity and genomic stability. Cancer is associated with global loss of DNA methylation, leading to cell transformation and genomic instability. However, the precise mutational consequences of global hypomethylation have not been fully assessed.

SCIENTIFIC REPORTS (2023)

Add to Collection

Article Cell Biology

Systemic alterations in neutrophils and their precursors in early-stage chronic obstructive pulmonary disease

Theodore S. Kapellos, Kevin Babler, Wataru Fujii, Christina Nalkurthi, Anna C. Schaar, Lorenzo Bonaguro, Tal Pecht, Izabela Galvao, Shobhit Agrawal, Adem Saglam, Erica Dudkin, Amit Frishberg, Elena de Domenico, Arik Horne, Chantal Donovan, Richard Y. Kim, David Gallego-Ortega, Tessa E. Gillett, Meshal Ansari, Jonas Schulte-Schrepping, Nina Offermann, Ignazio Antignano, Burcu Sivri, Wenying Lu, Mathew S. Eapen, Martina van Uelft, Collins Osei-Sarpong, Maarten van den Berge, Hylke C. Donker, Harry J. M. Groen, Sukhwinder S. Sohal, Johanna Klein, Tina Schreiber, Andreas Feisst, Ali Oender Yildirim, Herbert B. Schiller, Martijn C. Nawijn, Matthias Becker, Kristian Haendler, Marc Beyer, Melania Capasso, Thomas Ulas, Jan Hasenauer, Carmen Pizarro, Fabian J. Theis, Philip M. Hansbro, Dirk Skowasch, Joachim L. Schultze

Summary: Systemic inflammation is a characteristic feature of late-stage severe lung disease, while the molecular, functional, and phenotypic changes in peripheral immune cells in the early stages of the disease remain poorly understood. In this study, using single-cell analyses, the researchers found that blood neutrophils are already increased in early-stage COPD, and the changes in their molecular and functional states correlate with the decline of lung function. Further investigation using a murine cigarette smoke exposure model revealed similar molecular changes in blood neutrophils and precursor populations in the blood and lung. The findings suggest that systemic molecular alterations in neutrophils and their precursors are present in the early stages of COPD, and may serve as potential therapeutic targets and biomarkers for early diagnosis and patient stratification.

CELL REPORTS (2023)

Add to Collection

Article Oncology

PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer

Peter H. J. Slootbeek, Joanneke K. Overbeek, Marjolijn J. L. Ligtenberg, Nielka P. van Erp, Niven Mehra

Summary: PARP inhibitors have shown great potential in the treatment of metastatic castration-resistant prostate cancer, with superior responses observed in patients with BRCA1 or BRCA2 gene mutations. Combination therapy with androgen receptor signaling inhibitors can prolong progression-free survival in HRRm patients, but has limited efficacy in the non-HRRm subgroup.

CANCER LETTERS (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.